Search

To date, the scaled-up manufacturing and efficient drug loading of exosomes are two existing challenges limiting the clinical translation of exosome-based drug delivery. Herein, we developed a facile magnetic extrusion method for preparing endosome-derived vesicles, also known as exosome mimetics (EMs), which share the same biological origin and similar morphology, composition, and biofunctions with native exosomes. The high yield and consistency of this magnetic extrusion method help to overcome the manufacturing bottleneck in exosome research. Moreover, the proposed standardized multi-step method readily facilitates the ammonium sulfate gradient approach to actively load chemodrugs such as doxorubicin into EMs. The engineered EMs developed and tested here exhibit comparable drug delivery properties as do native exosomes and potently inhibit tumor growth by delivering doxorubicin in an orthotopic breast tumor model. These findings demonstrate that EMs can be prepared in a facile and scaled-up manner as a promising biological nanomedicine for cancer drug delivery.

The present review work tries to explore the present status of the nano carriers in the delivery of anti cancer drugs. The shortcomings associated with the anticancer drugs like poor solubility, multiple resistance and less bioavailability is been investigating using different nano formulations. The recent advance work on nanoparticles for the delivery of anti tumor drugs is focused along with the different patents available. The different technologies available in the present scenario for the delivery of anti-cancers drugs are being highlightened.

In the world the biggest challenges to cure the cancer because of the abnormal cancer cells growth in the human body which is near to uncontrollable. These cells known as the malignant cell because it produced the cancer. There are several treatments for cancer such as surgery, chemotherapy, radiation treatment etc. however such treatments have major side effects like normal cell got killed, loss of hair, the surgery person skill also in consideration and high chances of reoccurrences. Due to such side effects these treatment drugs are less popular. To reduces such side effects the liposomal based treatments are the most preferable solution. The liposomes are the phospholipid bilayer vesicles and it has high encapsulation capacity. Therefore, liposomal based treatment plays significant role in the cancer treatment with less toxicity and other many advantages. The liposomal based drug pegylated liposomal doxorubicin and daunorubicin have advanced effect in the body. Furthermore, the development of the liposomes as immunoliposomes, ligand targeted and molecular targeting. This review explores the liposomal based drug delivery system, its advance effect on the cancer cells and clinically approve liposomes formulations.

International audience; Nucleoside and nucleotide analogs are essential tools in our limited arsenal in the fight against cancer. However, these structures face severe drawbacks such as rapid plasma degradation or hydrophilicity, limiting their clinical application. Here, different aspects of nucleoside and nucleotide analogs have been exposed, while providing their shortcomings. Aiming to improve their fate in the body and combating their drawbacks, two different approaches have been discussed, the prodrug and nanocarrier technologies. Finally, a novel approach called "PUFAylation" based on both the prodrug and nanocarrier technologies has been introduced, promising to be the supreme method to create a novel nucleoside or nucleotide analog based formulation, with enhanced efficacy and highly reduced toxicity.

Fluorination of graphene nanomaterials has multitude merits owing to the peculiar temperament of the carbon-fluorine (C-F) bond. However, the current synthesis modalities of fluorinated graphene (FG) are based on the usage of toxic materials at high temperatures, which are problematic to be used. The methods to overcome these problems are challenging for chemists. Ionic liquids (ILs) have been used in several chemical processes as auxiliaries and eco-friendly alternatives instead of volatile organic solvents because of their properties. Consequently, herein we exploited a highly effective and green process for the synthesis of FG at mild temperature (80 °C) by using ammonium fluoride salt as fluorine agent and a synthesized acidic IL ([TEA]+[TFA]–) as a solvent. Our goal was to synthesize enriched FG with a high degree of fluorination (66.4 wt.% of F) and F/C ratio (2.2), which measured and confirmed by XPS analysis. Subsequently, the obtained FG was used as a nanocarrier for delivery of curcumin to cancerous cells. The in-vitro results showed that these nanosheets possessed a higher Cur-loading efficiency (78.43%) than commercial FG (52.12%) due to the sheet-like structure with folded edges. This, in turn, translated into an excellent in-vitro anti-cancer effect when tested against cancerous cells.

Regenerative medicine seeks to assess how materials fundamentally affect cellular functions to improve retaining, restoring, and revitalizing damaged tissues and cancer therapy. As potential candidates in regenerative medicine, hydrogels have attracted much attention due to mimicking of native cell-extracellular matrix (ECM) in cell biology, tissue engineering, and drug screening over the past two decades. In addition, hydrogels with a high capacity for drug loading and sustained release profile are applicable in drug delivery systems. Recently, self-healing supramolecular hydrogels, as a novel class of biomaterials, are being used in preclinical trials with benefits such as biocompatibility, native tissue mimicry, and injectability via a reversible crosslink. Meanwhile, the localized therapeutics agent delivery is beneficial due to the ability to deliver more doses of therapeutic agents to the targeted site and the ability to overcome post-surgical complications, inflammation, and infections. These highly potential materials can help address the limitations of current drug delivery systems and the high clinical demand for customized drug release systems. To this aim, the current review presents the state-of-the-art progress of multifunctional and self-healable hydrogels for a broad range of applications in cancer therapy, tissue engineering, and regenerative medicine.

Nanomaterials are increasingly used as drug carriers for cancer therapy. Nanomaterials also appeal to researchers in the areas of cancer diagnosis and biomarker discovery. Several antitumor nanodrugs are currently being tested in preclinical and clinical trials and show promise in therapeutic and other settings. We review the development of nanomaterial drug carriers, including liposomes, polymer nanoparticles, dendritic polymers, and nanomicelles, for the diagnosis and treatment of various cancers. The prospects of nanomaterials as drug carriers for future clinical applications are also discussed.

A review of cytotoxicity associated with cancer treatments as presented in literature was discussed. In all the studies, the research is aware of the cytotoxic effects of the cancer drug and the delivery form such as nanotechnology-based delivery. The scope of the review was limited to showing 1) the need for modulating cytotoxicity and 2) how cytotoxicity has been controlled in actual studies on treatment plans in vivo and in vitro. Keywords: Cytotoxicity, in vivo, in vitro, nanotechnology, nanoparticles, apoptosis

The physicochemical properties of nanoparticles play critical roles in regulating nano-bio interactions. Whereas the effects of the size, shape, and surface charge of nanoparticles on their biological performances have been extensively investigated, the roles of nanoparticle mechanical properties in drug delivery, which have only been recognized recently, remain the least explored. This review article provides an overview of the impacts of nanoparticle mechanical properties on cancer drug delivery, including (1) basic terminologies of the mechanical properties of nanoparticles and techniques for characterizing these properties; (2) current methods for fabricating nanoparticles with tunable mechanical properties; (3) in vitro and in vivo studies that highlight key biological performances of stiff and soft nanoparticles, including blood circulation, tumor or tissue targeting, tumor penetration, and cancer cell internalization, with a special emphasis on the underlying mechanisms that control those complicated nano-bio interactions at the cellular, tissue, and organ levels. The interesting research and findings discussed in this review article will offer the research community a better understanding of how this research field evolved during the past years and provide some general guidance on how to design and explore the effects of nanoparticle mechanical properties on nano-bio interactions. These fundamental understandings, will in turn, improve our ability to design better nanoparticles for enhanced drug delivery.

© The Author(s) 2019., [Background]: Lack of effective tumor-specific delivery systems remains an unmet clinical challenge for successful translation of innovative therapies, such as, therapeutic oligonucleotides. In the past decade, exosomes have been suggested to be ideal drug delivery systems with application in a broad range of pathologies including cancer, due to their organotropic properties. Tumor-derived exosomes, having tumor-homing properties, can efficiently reach cancer cells and therefore behave as carriers for improved drug delivery to the primary tumor and metastases. However, due to their complex composition, and still undefined biological functions, safety concerns arise hampering their translation to the clinics., [Results]: We propose here the development of exosome-mimetic nanosystems (EMNs) that simulate natural tumor-derived exosomes with respect to their structure and functionality, but with a controlled composition, for the targeted delivery of therapeutic oligonucleotides to lung adenocarcinoma cells (microRNA-145 mimics). Making use of the well-known liposome technology, EMNs can be engineered, loaded with the therapeutic compounds, and tailored with specific proteins (integrin α6β4) providing them organotropic properties. EMNs show great similarities to natural exosomes with respect to their physicochemical properties, drug loading capacity, and ability to interact with the cancer target cells in vitro and in vivo, but are easier to manufacture, can be produced at high yields, and are safer by definition., [Conclusions]: We have designed a multifunctional nanoplatform mimicking exosomes, EMNs, and proved their potential to reach cancer cells with a similar efficient that tumor-derived exosomes but providing important advantages in terms of production methodology and regulations. Additionally, EMNs are highly versatile systems that can be tunable for a broader range of applications., This work was in part supported by grants from Instituto de Salud Carlos III (ISCIII) and European Regional Development Fund (FEDER) (CP12/03150, PI15/00828, and CB16/12/00328 from M.F. and PI16/0014, CIBERONC CB16/12/00295 from G.M.B). A.V.R. also acknowledges the fnancial support from the Spanish Ministry of Education, Culture, and Sport (FPU15/06595).

Over the past years, the emergence of various therapeutic approaches has attracted so much consideration, but chemotherapy remains the most effective way in experimental practice. However, due to obstacles and difficulties, there is a limitation for the additional clinical presentation of the outdated chemical treatments such as paclitaxel and doxorubicin. Some of the barriers are severe side effects, profound cytotoxicity, and low therapeutic efficacy. Drug delivery systems (DDS) such as polymeric micelles have been technologically advanced over the recent decades to advance the treatment efficacy and lessen the side effects incurred. The polymeric micelles self-assembled from amphiphilic polymers serve to sum up hydrophobic treatments in the core and regulate the discharge profile of the drugs through response towards stimuli of the tumor microenvironments, which in this case are pH, temperature, light, and reduction.

Research for synthesis of size-controlled carriers is currently challenging one. In this research paper, a method for size-controlled synthesis of biodegradable nanocarriers is proposed and described. Salting out method is suitable for both hydrophilic and hydrophobic drugs for the encapsulation on carriers. This synthetic method is based on polylactic acid (PLA) and non-ionic carboxymethyl cellulose (CMC) composed by CaCl2 as salting out agent. This method permits size-controlled synthesis of particles between 50 and 400 nm simply by varying the concentration of salting out agents. We have prepared cisplatin (CDDP)-loaded PLA-CMC nanocarriers by salting out method, with varying salting out agent (CaCl2) concentrations as 0.05, 0.2, 0.35 and 0.5 M. The nanocarriers were characterized for their size, surface charge and morphology by atomic force microscope, zeta potential analyser and transmission electron microscope, respectively. The encapsulation efficiency and in-vitro drug-releasing behaviour of the nanocarriers were investigated. The cytotoxicity effect of nanocarriers and drug-loaded nanocarriers was tested against MCF-7 breast cancer cell line.

Nanoparticles (NPs) have been continuously utilized for different implementations, most particularly for cancer drug delivery. A large number of NP-based drug delivery systems (DDSs) have been explored for cancer therapy and a variety of materials have been investigated as potential drug delivery materials to ameliorate the therapeutic potency and harmlessness of anticancer drugs. Proteins NPs like albumin, lactoglobulin and gelatin are considered as outstanding alternatives to be formulated into the nanostructure platforms in conjugation with anticancer drugs because of their safety, biodegradability and biocompatibility. Also, their uncomplicated preparation and modification can be carried out under mild conditions with no concern toward the utilization of hazardous reagents. Therefore, in this paper we present an overview on the different methods for formulation of protein nanostructure including emulsification, simple desolvation/coacervation, complex coacervation (self-assembled), and electrospray. We then review the application of protein NPs especially gelatin NPs (GNPs) as potential candidates in DDSs which can be achieved through internal [pH, matrix metalloproteinase (MMP)] stimuli-responsive smart platforms for cancer therapy. Finally, many of the current challenges, future development of GNPs and their integration into clinical practice were discussed. This paper may pave the way to disclose some details about the healthcare transformation of GNPs toward precision medicine.

Submitted by Ilídio Correia (icorreia@ubi.pt) on 2018-08-20T14:02:47Z No. of bitstreams: 1 2018 Melo Diogo CSB.pdf: 1940631 bytes, checksum: 9197b48e4c87e51c2b7a2ff078f5a4ed (MD5) Approved for entry into archive by Paulo Pessoa (pfep@ubi.pt) on 2018-08-23T09:03:11Z (GMT) No. of bitstreams: 1 2018 Melo Diogo CSB.pdf: 1940631 bytes, checksum: 9197b48e4c87e51c2b7a2ff078f5a4ed (MD5) Approved for entry into archive by Paulo Pessoa (pfep@ubi.pt) on 2018-08-23T09:03:37Z (GMT) No. of bitstreams: 1 2018 Melo Diogo CSB.pdf: 1940631 bytes, checksum: 9197b48e4c87e51c2b7a2ff078f5a4ed (MD5) Made available in DSpace on 2018-08-23T09:03:37Z (GMT). No. of bitstreams: 1 2018 Melo Diogo CSB.pdf: 1940631 bytes, checksum: 9197b48e4c87e51c2b7a2ff078f5a4ed (MD5) Previous issue date: 2018-07-17 info:eu-repo/semantics/publishedVersion

Polymeric nanoparticles and liposomes have been the platform of choice for nanoparticle-based cancer drug delivery applications over the past decade, but extensive research has revealed their limitations as drug delivery carriers. A hybrid class of nanoparticles, aimed at combining the advantages of both polymeric nanoparticles and liposomes, has received attention in recent years. These core/shell type nanoparticles, frequently referred to as lipid–polymer hybrid nanoparticles (LPNs), possess several characteristics that make them highly suitable for drug delivery. This review introduces the formulation methods used to synthesize LPNs and discusses the strategies used to treat cancer, such as by targeting the tumor microenvironment or vasculature. Finally, it discusses the challenges that must be overcome to realize the full potential of LPNs in the clinic. Published version

This paper presents chemotherapy scheduling of cancer patients using type 1 and type 2 fuzzy logic controllers which are optimized by genetic algorithm. To handle the uncertainties of the model, we introduce a method to adjust the foot print of uncertainty (FOU) in interval type 2 (IT2) fuzzy systems based on the amount of uncertainty. Based on previous researches, type two fuzzy logic is more effective than type 1 in handling uncertainties in a model. According to this fact, proposed method tries to change the FOU of fuzzy sets adaptively based on the amount of uncertainty in counting tumor cells which always exist in real world. In addition, we have introduced two new indices to evaluate the results. Simulation results show that the proposed method can control the drug regimens better than IT2 and type 1 (IT1) fuzzy controllers.

Chitosan is a versatile polysaccharide of biological origin. Due to the biocompatible and biodegradable nature of chitosan, it is intensively utilized in biomedical applications in scaffold engineering as an absorption enhancer, and for bioactive and controlled drug release. In cancer therapy, chitosan has multifaceted applications, such as assisting in gene delivery and chemotherapeutic delivery, and as an immunoadjuvant for vaccines. The present review highlights the recent applications of chitosan and chitosan derivatives in cancer therapy.

It is possible to generate oligonucleotide aptamers for a wide variety of target molecules using a process known as Systematic Evolution of Ligands by Exponential Enrichment. Researchers have successfully generated aptamers which recognize specific metal ions, small chemical compounds, peptides, proteins, saccharides, and even whole cells. Aptamers show much promise as future therapeutics and as drug targeting agents. A particularly active area of aptamer research in the past two years was development of aptamer based cancer therapeutics and development of aptamer based cancer drug delivery systems. Aptamers were also used to address inflammatory diseases, infectious diseases, cardiovascular diseases, and eye diseases.

Advancements in cancer drug delivery have led to the development of personalized oncology care through molecularly-driven targeted therapies. Understanding molecular and cellular mechanisms which drive tumor progression and resistance is critical in managing new treatment strategies which have shifted from empiric to biomarker-directed therapy selection. Biomarker-directed therapies have improved clinical outcomes in multiple malignancies as monotherapy and in combination with other treatment modalities, however the changing scope of treatment options presents new opportunities and challenges for research. Furthermore, pharmacogenetics may provide a rationale method of personalizing anticancer drug dosing and supportive care management for oncology patients. This chapter reviews biomarker classifications and pharmacogenetics in anticancer therapy and supportive care. Examples of biomarker-directed therapies and clinical assays, in addition to future directions of molecular profiling in oncology therapy management are discussed.

In order to efficiently deliver anticancer agents to tumors, biocompatible nanoparticles or bioconjugates, including antibody-drug conjugates (ADCs), have recently been designed, synthesized, and tested, some even in clinical trials. Controlled delivery can be enhanced by changing specific design characteristics of the bioconjugate such as its size, the nature of the payload, and the surface features. The delivery of macromolecular drugs to cancers largely relies on the leaky nature of the tumor vasculature compared with healthy vessels in normal organs. When administered intravenously, macromolecular bioconjugates and nanosized agents tend to circulate for prolonged times, unless they are small enough to be excreted by the kidney or stealthy enough to evade the macrophage phagocytic system (MPS), formerly the reticulo-endothelial system (RES). Therefore, macromolecular bioconjugates and nanosized agents with long circulation times leak preferentially into tumor tissue through permeable tumor vessels and are then retained in the tumor bed due to reduced lymphatic drainage. This process is known as the enhanced permeability and retention (EPR) effect. However, success of cancer drug delivery only relying on the EPR effect is still limited. To cure cancer patients, further improvement of drug delivery is required by both designing superior agents and enhancing EPR effects. In this Review, we describe the basis of macromolecular or nanosized bioconjugate delivery into cancer tissue and discuss current diagnostic methods for evaluating leakiness of the tumor vasculature. Then, we discuss methods to augment conventional "permeability and retention" effects for macromolecular or nanosized bioconjugates in cancer tissue.

Nanoparticles are rapidly being developed and trialed to overcome several limitations of traditional drug delivery systems and are coming up as a distinct therapeutics for cancer treatment. Conventional chemotherapeutics possess some serious side effects including damage of the immune system and other organs with rapidly proliferating cells due to nonspecific targeting, lack of solubility, and inability to enter the core of the tumors resulting in impaired treatment with reduced dose and with low survival rate. Nanotechnology has provided the opportunity to get direct access of the cancerous cells selectively with increased drug localization and cellular uptake. Nanoparticles can be programmed for recognizing the cancerous cells and giving selective and accurate drug delivery avoiding interaction with the healthy cells. This review focuses on cell recognizing ability of nanoparticles by various strategies having unique identifying properties that distinguish them from previous anticancer therapies. It also discusses specific drug delivery by nanoparticles inside the cells illustrating many successful researches and how nanoparticles remove the side effects of conventional therapies with tailored cancer treatment.

Drug repurpose or reposition is recently recognized as a high-performance strategy for developing therapeutic agents for cancer treatment. This approach can significantly reduce the risk of failure, shorten R&D time, and minimize cost and regulatory obstacles. On the other hand, nanotechnology-based delivery systems are extensively investigated in cancer therapy due to their remarkable ability to overcome drug delivery challenges, enhance tumor specific targeting, and reduce toxic side effects. With increasing knowledge accumulated over the past decades, nanoparticle formulation and delivery have opened up a new avenue for repurposing drugs and demonstrated promising results in advanced cancer therapy. In this review, recent developments in nano-delivery and formulation systems based on soft (i.e., DNA nanocages, nanogels, and dendrimers) and condensed (i.e., noble metal nanoparticles and metal–organic frameworks) nanomaterials, as well as their theranostic applications in drug repurpose against cancer are summarized.

The enhanced permeability and retention effect of nanoparticles has become the gold standard principle for cancer drug delivery systems, holding the promise of safe, simple and effective therapy. Nevertheless, due to its poor clinical translation, many recent papers describe the limitations of this EPR effect. Hence, efforts should be provided to overcome these barriers allowing the enhancement of nanomedicines on the market. This communication reviews three main strategies to enhance the EPR effect: (i) the normalization of the tumor vasculature; (ii) the possibility to include collagenase or hyaluronidase into the tumor microenvironment to simultaneously improve the transport and reduce the interstitial fluid pressure and (iii) the increase of the tumor permeability using external or internal stimuli.

Metastasis contributes to over 90% of cancer-related deaths. Numerous nanoparticle platforms have been developed to target and treat cancer, yet efficient delivery of these systems to the appropriate site remains challenging. Leukocytes, which share similarities to tumor cells in terms of their transport and migration through the body, are well suited to serve as carriers of drug delivery systems to target cancer sites.This review focuses on the use and functionalization of leukocytes for therapeutic targeting of metastatic cancer. Tumor cell and leukocyte extravasation, margination in the bloodstream, and migration into soft tissue are discussed, along with the potential to exploit these functional similarities to effectively deliver drugs. Current nanoparticle-based drug formulations for the treatment of cancer are reviewed, along with methods to functionalize delivery vehicles to leukocytes, either on the surface and/or within the cell. Recent progress in this area, both in vitro and in vivo, is also discussed, with a particular emphasis on targeting cancer cells in the bloodstream as a means to interrupt the metastatic process.Leukocytes interact with cancer cells both in the bloodstream and at the site of solid tumors. These interactions can be utilized to effectively deliver drugs to targeted areas, which can reduce both the amount of drug required and various nonspecific cytotoxic effects within the body. If drug delivery vehicle functionalization does not interfere with leukocyte function, this approach may be utilized to neutralize tumor cells in the bloodstream to prevent the formation of new metastases, and also to deliver drugs to metastatic sites within tissues.

Successful cancer management depends on accurate diagnostics along with specific treatment protocols. Current diagnostic techniques need to be improved to provide earlier detection capabilities, and traditional chemotherapy approaches to cancer treatment are limited by lack of specificity and systemic toxicity. This review highlights advances in nanotechnology that have allowed the development of multifunctional platforms for cancer detection, therapy, and monitoring. Nanomaterials can be used as MRI, optical imaging, and photoacoustic imaging contrast agents. When used as drug carriers, nanoformulations can increase tumor exposure to therapeutic agents and result in improved treatment effects by prolonging circulation times, protecting entrapped drugs from degradation, and enhancing tumor uptake through the enhanced permeability and retention effect as well as receptor-mediated endocytosis. Multiple therapeutic agents such as chemotherapy, antiangiogenic, or gene therapy agents can be simultaneously delivered by nanocarriers to tumor sites to enhance the effectiveness of therapy. Additionally, imaging and therapy agents can be co-delivered to provide seamless integration of diagnostics, therapy, and follow-up, and different therapeutic modalities such as chemotherapy and hyperthermia can be co-administered to take advantage of synergistic effects. Liposomes, metallic nanoparticles, polymeric nanoparticles, dendrimers, carbon nanotubes, and quantum dots are examples of nanoformulations that can be used as multifunctional platforms for cancer theranostics. Nanomedicine approaches in cancer have great potential for clinically translatable advances that can positively impact the overall diagnostic and therapeutic process and result in enhanced quality of life for cancer patients. However, a concerted scientific effort is still necessary to fully explore long-term risks, effects, and precautions for safe human use.

Polymeric nanomaterials have the potential to improve upon present chemotherapy delivery methods. They successfully reduce side effects while increasing dosage, increase residence time in the body, offer a sustained and tunable release, and have the ability to deliver multiple drugs in one carrier. However, traditional nanomaterial formulations have not produced highly therapeutic formulations to date due to their passive delivery methods and lack of rapid drug release at their intended site. In this paper, we have focused on a few “smart” technologies that further enhance the benefits of typical nanomaterials. Temperature and pH-responsive drug delivery devices were reviewed as methods for triggering release of encapsulating drugs, while aptamer and ligand conjugation were discussed as methods for targeted and intracellular delivery, with emphases onin vitroandin vivoworks for each method.